Low-dose Thimerosal in Pediatric Vaccines: Adverse Effects in Perspective.
From PubMed:
Environmental Research Magazine
Vaccines are prophylactics used as the first line of intervention to prevent, control and eradicate infectious diseases. Young children (before the age of six months) are the demographic group most exposed to recommended/mandatory vaccines preserved with Thimerosal and its metabolite ethylmercury (EtHg). Particularly in the less-developed countries, newborns, neonates, and young children are exposed to EtHg because it is still in several of their pediatric vaccines and mothers are often immunized with Thimerosal-containing vaccines (TCVs) during pregnancy. While the immunogenic component of the product has undergone more rigorous testing, Thimerosal, known to have neurotoxic effects even at low doses, has not been scrutinized for the limit of tolerance alone or in combination with adjuvant-Al during immaturity or developmental periods (pregnant women, newborns, infants, and young children). Scientific evidence has shown the potential hazards of Thimerosal in experiments that modeled vaccine-EtHg concentrations. Observational population studies have revealed uncertainties related to neurological effects. However, consistently, they showed a link of EtHg with risk of certain neurodevelopment disorders, such as tic disorder, while clearly revealing the benefits of removing Thimerosal from children's vaccines (associated with immunological reactions) in developed countries. So far, only rich countries have benefited from withdrawing the risk of exposing young children to EtHg. Regarding Thimerosal administered to the very young, we have sufficient studies that characterize a state of uncertainty: the collective evidence strongly suggests that Thimerosal exposure is associated with adverse neurodevelopmental outcomes. It is claimed that the continued use of Thimerosal in the less-developed countries is due to the cost to change to another preservative, such as 2-phenoxyethanol. However, the estimated cost increase per child in the first year of life is lower than estimated lifetime cost of caring for a child with a neurodevelopmental disorder, such tic disorder. The evidence indicates that Thimerosal-free vaccine options should be made available in developing countries.
To David m Burd- Please do give your complete post on this subject. There is still much misinformation on this topic, whether it be U.S. or developing nations.
And who told the authors of this piece that the mercury in vaccines is "low dose" ?? I dont think any mercury toxicologist would describe it as "low".
Remember friends the words of the great Dr. Boyd E. Haley- " What would be surprising would be if mercury in vaccines DIDNT cause a problem ." (Not quite exact quote ) Oh sorry, I guess we have to refer to Dr. Haley as the " DISCREDITED SCIENTIST" . All persons who tell the truth about vaccines are automatically referred to in this manner .
Posted by: Cherry Misra | December 16, 2016 at 12:45 PM
"It is claimed that the continued use of Thimerosal in the less-developed countries is due to the cost to change to another preservative, such as 2-phenoxyethanol. However, the estimated cost increase per child in the first year of life is lower than estimated lifetime cost of caring for a child with a neurodevelopmental disorder, such tic disorder."
So if the economic cost of using a less toxic ingredient was more than the cost of caring for a damaged child, it would be ok to damage more children? This logic is barbaric.
Posted by: Linda1 | December 15, 2016 at 09:59 PM
Thanks(!) AoA leaders for your sharp eyes finding this Paper to be published in Environmental Research, Volume 152, Jan 2017, pages 280-293. I have a caveat however, as its author addresses "poor" countries receiving Thimerosal-loaded vaccines for children, while seeming to think it is not a critical situation (anymore) for such as the U.S.
My recent Posts here (in October and November) have documented the vast majority of U.S. babies are being injected with two .25 ml doses of the Thimerosal-loaded flu vaccine at age 6 months, and a second dose four weeks later; with more Thimerosal-doses every year thereafter. Each such dose contains 12.5 micrograms of ethylmercury (EtHg), then 25 micrograms EtHg in each dose over the age of 36 months, the subject of this Environmental Research Paper.
There is only one manufacturer of the pediatric .25 ml flu-vaccine dose claimed to be without EtHg; It is Sanofi Pasteur, yet rock-solid Vaccine Industry publications document their annual production of single-dose prefilled .25 ml syringes are not even 10% of the injected doses going into babies at six months, again 4 weeks later.
Here is a vivid example of Sanofi Pasteur telling U.S. health professionals to draw .25 ml pediatric flu doses from 5.0 ml multi-dose flu vaccine vials preserved with EtHg; this document also indicates there was no available single-dose .25 ml doses available, and this was published only a few years ago.
http://www.fluzone.com/health-care-professionals/fluzone-pediatric-vaccine.cfm
I plan to soon submit another more complete Post on this topic; Merry Christmas wishes to all.
Posted by: david m burd | December 15, 2016 at 08:40 AM